DALLAS, March 27, 2025 — Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today announced that Ashish Patel, PhD, has joined the company as Senior Vice President, Sales and Marketing. Dr. Patel is a recognized leader with proven results across brand, sales and research and development management for some of the world’s most recognized startup biotech and pharmaceutical organizations.
“With his unique blend of scientific and commercial expertise, particularly in the treatment of retinal diseases, Dr. Patel is well-equipped to drive Nanoscope’s sales and marketing strategy as we move towards commercialization of our optogenetic therapies,” said Sulagna Bhattacharya, co-founder and CEO of Nanoscope Therapeutics.
Dr. Patel has extensive experience in aligning scientific and commercial insights to inform strategic and business decisions with a focus on patients. Most recently, he served as Vice President of Sales for Iveric Bio (now Astellas), launching IZERVAY™, a treatment for geographic atrophy. Prior to Iveric, Dr. Patel spearheaded marketing and launch efforts for Novartis’ BEOVU®, used to treat chronic eye conditions, including wet age-related macular degeneration (AMD). His tenure at Bayer spanned over a decade, during which he held multiple brand, sales and research management roles. Notably, he served as the global launch lead for the fastest-growing indication within Bayer’s blockbuster EYLEA® retina business. He began his career as a senior research and development scientist with Novartis.
Dr. Patel received a Master of Business Administration from New York University Stern School of Business and holds a PhD in physiology and biophysics from Stony Brook University. Dr. Patel was a graduate fellow in molecular biology at the Massachusetts Institute of Technology and earned his Bachelor of Science in biophysics from the University of Southern California.
“Nanoscope is at the precipice of being the first to deliver life changing, mutation-independent therapies to patients with the highest unmet needs in retina,” said Dr. Patel. “I’m excited to join the accomplished team at Nanoscope, and I look forward to helping lead our commercialization and launch preparations as we progress in our mission to help the millions of patients worldwide impaired by retinal degenerative diseases for which no treatment currently exists.”
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com
SOURCE Nanoscope Therapeutics